McIndoe W A, McLean M R, Jones R W, Mullins P R
Obstet Gynecol. 1984 Oct;64(4):451-8.
Nine hundred and forty-eight patients with carcinoma in situ (CIS) of the cervix diagnosed histologically have been followed from five to 28 years. Among the 817 patients who had normal cytology follow-up, 12 (1.5%) developed invasive carcinoma. A second group of 131 patients continued to produce abnormal cytology consistent with cervical neoplasia, and 29 (22%) of them developed invasive carcinoma of the cervix or vaginal vault. Patients with continuing abnormal cytology after initial management of CIS of the cervix are 24.8 times more likely to develop invasive carcinoma than women who have normal follow-up cytology. Further, when compared with the population at large, the chances of patients with normal follow-up cytology developing invasive cervical or vaginal vault carcinoma increase 3.2-fold over women who have never had CIS of the cervix.
948例经组织学诊断为宫颈原位癌(CIS)的患者接受了5至28年的随访。在817例细胞学随访正常的患者中,有12例(1.5%)发生了浸润性癌。第二组131例患者持续出现与宫颈肿瘤一致的异常细胞学结果,其中29例(22%)发生了宫颈或阴道穹窿浸润性癌。宫颈原位癌初始治疗后细胞学持续异常的患者发生浸润性癌的可能性是随访细胞学正常女性的24.8倍。此外,与普通人群相比,随访细胞学正常的患者发生宫颈或阴道穹窿浸润性癌的几率比从未患过宫颈原位癌的女性增加了3.2倍。